First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

Minami Omura; Takeo Kosaka; Eriko Aimono; Kohei Nakamura; Hiroshi Hongo; Shuji Mikami; Hiroshi Nishihara; Mototsugu Oya

doi:10.1002/iju5.12383

First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

Minami Omura, Takeo Kosaka, Eriko Aimono, Kohei Nakamura, Hiroshi Hongo, Shuji Mikami, Hiroshi Nishihara, Mototsugu Oya

研究成果: Article › 査読

4 被引用数 (Scopus)

抄録

Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

本文言語	English
ページ（範囲）	41-44
ページ数	4
ジャーナル	IJU Case Reports
巻	5
号	1
DOI	https://doi.org/10.1002/iju5.12383
出版ステータス	Published - 2022 1月

ASJC Scopus subject areas

泌尿器学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.1002/iju5.12383

他のファイルとリンク

引用スタイル

@article{97050398452a48d7bc52f6074a6e78f4,

title = "First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations",

abstract = "Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.",

author = "Minami Omura and Takeo Kosaka and Eriko Aimono and Kohei Nakamura and Hiroshi Hongo and Shuji Mikami and Hiroshi Nishihara and Mototsugu Oya",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association",

year = "2022",

month = jan,

doi = "10.1002/iju5.12383",

language = "English",

volume = "5",

pages = "41--44",

journal = "IJU Case Reports",

issn = "2577-171X",

publisher = "John Wiley and Sons Inc.",

number = "1",

}

TY - JOUR

T1 - First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

AU - Omura, Minami

AU - Kosaka, Takeo

AU - Aimono, Eriko

AU - Nakamura, Kohei

AU - Hongo, Hiroshi

AU - Mikami, Shuji

AU - Nishihara, Hiroshi

AU - Oya, Mototsugu

PY - 2022/1

Y1 - 2022/1

N2 - Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

AB - Introduction: Deoxyribonucleic acid repair gene mutations are now being studied in a variety of solid tumors, with the hope of predicting prognosis, pathogenesis, and treatment outcomes. Case presentation: We report the case of a Japanese patient with advanced castration-resistant prostate cancer who exhibited a prominent response to platinum therapy and had coexisting BRCA2 and PTEN mutations according to retrospective multigene panel analysis. Conclusion: Through a review of clinical outcomes and genetic/pathologic profiling, the presented case provides insights into future management strategies based on the tumor genetic status.

UR - http://www.scopus.com/inward/record.url?scp=85117344726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117344726&partnerID=8YFLogxK

U2 - 10.1002/iju5.12383

DO - 10.1002/iju5.12383

M3 - Article

AN - SCOPUS:85117344726

SN - 2577-171X

VL - 5

SP - 41

EP - 44

JO - IJU Case Reports

JF - IJU Case Reports

IS - 1

ER -

First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル